The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform

Chia-jui Yang - One of the best experts on this subject based on the ideXlab platform.

  • comparison of serological responses to single dose azithromycin 2 g versus Benzathine Penicillin g in the treatment of early syphilis in hiv infected patients in an area of low prevalence of macrolide resistant treponema pallidum infection
    Journal of Antimicrobial Chemotherapy, 2016
    Co-Authors: Chia-jui Yang, Szu-min Hsieh, Wang-huei Sheng, Kuan-yeh Lee, Hungjen Tang, Suiyuan Chang, Yuanti Lee, Shangping Yang, Chienching Hung
    Abstract:

    Objectives Effectiveness of single-dose azithromycin (2 g) in the treatment of early syphilis among HIV-infected patients has rarely been evaluated in the era of combination ART. Methods Consecutive HIV-infected patients with early syphilis, who received 2 g single-dose azithromycin or 2.4 MU Benzathine Penicillin G, between 2007 and 2014, were prospectively observed. Genotypic resistance to macrolides was determined in Treponema pallidum isolates identified from clinical specimens using PCR assays. Rapid plasma reagin (RPR) titres were determined at baseline and every 3 months after treatment. Primary outcome was a decline of RPR titre by ≥4-fold at 12 months after treatment. Results During the study period, 162 HIV-infected patients with early syphilis received Benzathine Penicillin G and 237 patients received azithromycin. At 12 months follow-up, the serological response rate for Penicillin and azithromycin groups was 61.1% and 56.5% (P = 0.41), respectively; respective response rate was 61.1% and 65.9% (P = 0.49) if we only included patients infected with T. pallidum not harbouring macrolide resistance in the azithromycin group. In multivariate analysis, RPR titres ≥1:32 (OR 2.56; 95% CI 1.55-4.21) and prior syphilis (OR 0.54; 95% CI 0.35-0.81) were predictors of serological response. Most common adverse effects of azithromycin included diarrhoea (52.7%), nausea (22.4%), abdominal pain (18.6%), bloating (17.7%) and lassitude/somnolence (27.4%). Conclusions In the setting of a low prevalence of macrolide-resistant T. pallidum, 2 g single-dose azithromycin achieved a similar serological response to Benzathine Penicillin G in HIV-infected patients with early syphilis. Major adverse effects of azithromycin were gastrointestinal symptoms and lassitude/somnolence.

  • comparison of serological response to doxycycline versus Benzathine Penicillin g in the treatment of early syphilis in hiv infected patients a multi center observational study
    PLOS ONE, 2014
    Co-Authors: Chia-jui Yang, Nan-yao Lee, Yuag-meng Liu, Hungjen Tang, Jen Chih Tsai, Yu Huei Lin, Ni Jiin Shen, Wen Chi Huang, Chen Hsiang Lee
    Abstract:

    Background While doxycycline is recommended as an alternative treatment of syphilis in patients with Penicillin allergy or intolerance, clinical studies to compare serological response to doxycycline versus Benzathine Penicillin in treatment of early syphilis among HIV-infected patients remain sparse.

  • Jarisch-Herxheimer reaction among HIV-positive patients with early syphilis: azithromycin versus Benzathine Penicillin G therapy
    Journal of the International AIDS Society, 2014
    Co-Authors: Mao-song Tsai, Chia-jui Yang, Nan-yao Lee, Szu-min Hsieh, Yu-hui Lin, Hsin-yun Sun, Wang-huei Sheng, Kuan-yeh Lee, Shan-ping Yang, Wen-chun Liu
    Abstract:

    Introduction : The Jarisch-Herxheimer reaction, a febrile inflammatory reaction that often occurs after the first dose of chemotherapy in spirochetal diseases, may result in deleterious effects to patients with neurosyphilis and to pregnant women. A single 2-g oral dose of azithromycin is an alternative treatment to Benzathine Penicillin G for early syphilis in areas with low macrolide resistance. With its potential anti-inflammatory activity, the impact of azithromycin on the incidence of the Jarisch-Herxheimer reaction in HIV-positive patients with early syphilis has rarely been investigated. Methods : In HIV-positive patients with early syphilis, the Jarisch-Herxheimer reaction was prospectively investigated using the same data collection form in 119 patients who received Benzathine Penicillin G between 2007 and 2009 and 198 who received azithromycin between 2012 and 2013, when shortage of Benzathine Penicillin G occurred in Taiwan. Between 2012 and 2013, polymerase chain reaction (PCR) assay was performed to detect Treponema pallidum DNA in clinical specimens, and PCR restriction fragment length polymorphism of the 23S ribosomal RNA was performed to detect point mutations (2058G or A2059G) that are associated with macrolide resistance. Results : The overall incidence of the Jarisch-Herxheimer reaction was significantly lower in patients receiving azithromycin than those receiving Benzathine Penicillin G (14.1% vs. 56.3%, p< 0.001). The risk increased with higher rapid plasma reagin (RPR) titres (adjusted odds ratio [AOR] per 1-log 2 increase, 1.21; confidence interval [CI], 1.04–1.41), but decreased with prior Penicillin therapy for syphilis (AOR, 0.37; 95% CI, 0.19–0.71) and azithromycin treatment (AOR, 0.15; 95% CI, 0.08–0.29). During the study period, 310 specimens were obtained from 198 patients with syphilis for PCR assays, from whom T. pallidum was identified in 76 patients, one of whom (1.3%) was found to be infected with T. pallidum harbouring the macrolide resistance mutation (A2058G). In subgroup analyses confined to the 75 patients infected with T. pallidum lacking resistance mutation, a statistically significantly lower risk for the Jarisch-Herxheimer reaction following azithromycin treatment was noted. Conclusions : Treatment with azithromycin was associated with a lower risk for the Jarisch-Herxheimer reaction than that with Benzathine Penicillin G in HIV-positive patients with early syphilis. Previous Benzathine Penicillin G therapy for syphilis decreased the risk, whereas higher RPR titres increased the risk, for the reaction. Keywords: sexually transmitted diseases; spirochetal disease; macrolides; macrolide resistance; immunomodulation. (Published: 28 August 2014) Citation: Tsai M-S et al. Journal of the International AIDS Society 2014, 17 :18993 http://www.jiasociety.org/index.php/jias/article/view/18993 | http://dx.doi.org/10.7448/IAS.17.1.18993

  • Jarisch-Herxheimer reaction among HIV-positive patients with early syphilis: azithromycin versus Benzathine Penicillin G therapy
    Wiley, 2014
    Co-Authors: Mao-song Tsai, Chia-jui Yang, Nan-yao Lee, Szu-min Hsieh, Yu-hui Lin, Hsin-yun Sun, Wang-huei Sheng, Kuan-yeh Lee, Shan-ping Yang, Wen-chun Liu
    Abstract:

    Introduction: The Jarisch-Herxheimer reaction, a febrile inflammatory reaction that often occurs after the first dose of chemotherapy in spirochetal diseases, may result in deleterious effects to patients with neurosyphilis and to pregnant women. A single 2-g oral dose of azithromycin is an alternative treatment to Benzathine Penicillin G for early syphilis in areas with low macrolide resistance. With its potential anti-inflammatory activity, the impact of azithromycin on the incidence of the Jarisch-Herxheimer reaction in HIV-positive patients with early syphilis has rarely been investigated. Methods: In HIV-positive patients with early syphilis, the Jarisch-Herxheimer reaction was prospectively investigated using the same data collection form in 119 patients who received Benzathine Penicillin G between 2007 and 2009 and 198 who received azithromycin between 2012 and 2013, when shortage of Benzathine Penicillin G occurred in Taiwan. Between 2012 and 2013, polymerase chain reaction (PCR) assay was performed to detect Treponema pallidum DNA in clinical specimens, and PCR restriction fragment length polymorphism of the 23S ribosomal RNA was performed to detect point mutations (2058G or A2059G) that are associated with macrolide resistance. Results: The overall incidence of the Jarisch-Herxheimer reaction was significantly lower in patients receiving azithromycin than those receiving Benzathine Penicillin G (14.1% vs. 56.3%, p

Dianchang Liu - One of the best experts on this subject based on the ideXlab platform.

  • availability of Benzathine Penicillin g for syphilis treatment in shandong province eastern china
    BMC Health Services Research, 2019
    Co-Authors: Xinlong Chen, Yanling Gan, Tongsheng Chu, Dianchang Liu
    Abstract:

    The shortage of Benzathine Penicillin G (BPG) worldwide presents a major challenge in the treatment of syphilis. Its availability for syphilis treatment has not been adequately evaluated in China. Two surveys were conducted among hospitals providing sexually transmitted infection clinical services in Shandong Province in 2012 and 2018. Data on the basic information and BPG availability of the surveyed hospitals and related factors were collected and analyzed using SPSS 17.0. A total of 433 and 515 hospitals were surveyed in 2012 and 2018, respectively. A significant difference in BPG availability was observed among different levels and types of hospitals both in 2012 (X2 = 9.747, p = 0.008; X2 = 37.167, p = 0.000) and 2018 (X2 = 11.775, p = 0.003; X2 = 28.331, p = 0.000). The BPG availability among surveyed hospitals increased from 45.0% in 2012 to 56.4% in 2018 (X2 = 11.131, p = 0.001). The BPG availability was higher in 2018 than in 2012 among county-level hospitals (52.0% vs. 40.8%, X2 = 7.783, p = 0.005), general western medicine hospitals (62.1% vs. 50.0%, X2 = 6.742, p = 0.009), maternal and child health hospitals (57.1% vs. 26.9%, X2 = 13.906, p = 0.000), and public hospitals (56.8% vs. 45.0%, X2 = 11.361, p = 0.001). However, the county-level availability of BPG (at least one hospital has BPG in a county-level unit) has not improved between 2012 and 2018 (65.93% vs. 70.34%; X2 = 0.563, p = 0.453). The absences of clinical needs, restriction of clinical antibacterial drugs, and lack of qualifications for providing syphilis treatment were the major reasons for the low BPG availability of hospitals. BPG availability for syphilis treatment in Shandong Province remains low and presents disparities among different levels and types of hospitals, although it has been improved in recent years. The low availability of BPG for syphilis treatment in China is related to its clinical use by doctors rather than the market supply. Health care reforms should further improve the availability and accessibility of health services.

  • Additional file 1: of Availability of Benzathine Penicillin G for syphilis treatment in Shandong Province, Eastern China
    2019
    Co-Authors: Xinlong Chen, Yanling Gan, Tongsheng Chu, Dianchang Liu
    Abstract:

    Questionnaire on availability of Benzathine Penicillin G in medical institutions. (DOCX 13 kb

  • Availability of Benzathine Penicillin G for syphilis treatment in Shandong Province, Eastern China
    BMC, 2019
    Co-Authors: Xinlong Chen, Yanling Gan, Tongsheng Chu, Dianchang Liu
    Abstract:

    Abstract Background The shortage of Benzathine Penicillin G (BPG) worldwide presents a major challenge in the treatment of syphilis. Its availability for syphilis treatment has not been adequately evaluated in China. Methods Two surveys were conducted among hospitals providing sexually transmitted infection clinical services in Shandong Province in 2012 and 2018. Data on the basic information and BPG availability of the surveyed hospitals and related factors were collected and analyzed using SPSS 17.0. Results A total of 433 and 515 hospitals were surveyed in 2012 and 2018, respectively. A significant difference in BPG availability was observed among different levels and types of hospitals both in 2012 (X2 = 9.747, p = 0.008; X2 = 37.167, p = 0.000) and 2018 (X2 = 11.775, p = 0.003; X2 = 28.331, p = 0.000). The BPG availability among surveyed hospitals increased from 45.0% in 2012 to 56.4% in 2018 (X2 = 11.131, p = 0.001). The BPG availability was higher in 2018 than in 2012 among county-level hospitals (52.0% vs. 40.8%, X2 = 7.783, p = 0.005), general western medicine hospitals (62.1% vs. 50.0%, X2 = 6.742, p = 0.009), maternal and child health hospitals (57.1% vs. 26.9%, X2 = 13.906, p = 0.000), and public hospitals (56.8% vs. 45.0%, X2 = 11.361, p = 0.001). However, the county-level availability of BPG (at least one hospital has BPG in a county-level unit) has not improved between 2012 and 2018 (65.93% vs. 70.34%; X2 = 0.563, p = 0.453). The absences of clinical needs, restriction of clinical antibacterial drugs, and lack of qualifications for providing syphilis treatment were the major reasons for the low BPG availability of hospitals. Conclusions BPG availability for syphilis treatment in Shandong Province remains low and presents disparities among different levels and types of hospitals, although it has been improved in recent years. The low availability of BPG for syphilis treatment in China is related to its clinical use by doctors rather than the market supply. Health care reforms should further improve the availability and accessibility of health services

  • availability of Benzathine Penicillin g for syphilis treatment in shandong province eastern china
    Social Science Research Network, 2018
    Co-Authors: Dianchang Liu, Tongsheng Chu, Xinlong Chen
    Abstract:

    Background: Penicillin is still an essential antibiotic for the treatment and prevention of syphilis. The shortage of Benzathine Penicillin G (BPG) worldwide presents a major challenge in the Penicillin treatment of syphilis. Its availability for syphilis treatment has not been adequately evaluated in China. Methods: Two surveys were conducted among hospitals providing sexually transmitted infection clinical services in Shandong Province in 2012 and 2018. Data on the basic information and BPG availability of the surveyed hospitals and related factors were collected and analyzed using SPSS 17·0. Findings: A total of 433 and 515 hospitals were surveyed in 2012 and 2018, respectively. A significant difference in BPG availability was observed among different levels and types of hospitals both in 2012 (X2=9·747, p=0·008; X2= 37·167, p=0·000) and 2018 (X2=11·775, p=0·003; X2= 28·331, p=0·000). The BPG availability among surveyed hospitals increased from 45·0% in 2012 to 56·4% in 2018 (X2=11·131, p=0·001). The BPG availability was higher in 2018 than in 2012 among county-level hospitals (52·0% vs. 40·8%, X2=7·783, p=0·005), general western medicine hospitals (62·1% vs. 50·0%, X2=6·742, p=0·009), maternal and child health hospitals (57·1% vs. 26·9%, X2=13·906, p=0·000), and public hospitals (56·8% vs. 45·0%, X2=11·361, p=0·001). However, the county-level availability of BPG (at least one hospital has BPG in a county-level unit) has not improved between 2012 and 2018 (65·93% vs. 70·34%; X2=0·563, p=0·453). The absences of clinical needs, restriction of clinical antibacterial drugs, and lack of qualifications for providing syphilis treatment were the major reasons for the low BPG availability of hospitals. Interpretation: The BPG availability for syphilis treatment in Shandong Province has been improved in recent years, although it remains low and presents disparities among different levels and types of hospitals. Its low availability for syphilis treatment in China is related to its clinical use by doctors rather than its market supply. Health care reforms should further improve availability and accessibility of health services. Funding: Shandong Provincial Key R&D Plan. Declaration of Interest: We declare no competing interests.

  • Comparison of Doxycycline and Benzathine Penicillin G for the Treatment of Early Syphilis.
    Acta dermatovenerologica Croatica : ADC, 2017
    Co-Authors: Hailu Xiao, Tongsheng Chu, Dianchang Liu, Rongtao Zheng, Jianling Hou, Shengjia Zhang, Hongqing Tian, Fu-ren Zhang
    Abstract:

    Doxycycline is the preferred recommended second-line treatment for the treatment of early syphilis. Recent reports showed a declining efficacy trend of doxycycline in treatment of early syphilis. The aim of our study was to assess the serological response to the treatment for early syphilis with doxycycline compared with Benzathine Penicillin G and evaluate whether doxycycline is still an effective agent for the treatment of early syphilis. A record-based retrospective study was conducted. Patients were diagnosed with early syphilis in an sexually transmitted disease (STD) clinic from January 1, 2008 to December 31, 2014. They were treated with a single dose of Benzathine Penicillin G 2.4MU or oral doxycycline 100 mg twice daily for 14 days. Pearson’s chi-squared test was used for data analysis. 601 cases were included in the final study sample: 105 (17.5%) patients received a 14-day course of doxycycline (doxycycline group), and 496 (82.5%) patients received single-dose Benzathine Penicillin G (BPG group). The serological responses at 6 months and 12 months after treatment were compared. No statistically significant differences were found between the two groups at 6 months (69.52% vs. 75.00%, P=0.245), and at 12 months (92.38% vs. 96.17%, P=0.115). Doxycycline is still an effective agent for the treatment of early syphilis.

Xinlong Chen - One of the best experts on this subject based on the ideXlab platform.

  • availability of Benzathine Penicillin g for syphilis treatment in shandong province eastern china
    BMC Health Services Research, 2019
    Co-Authors: Xinlong Chen, Yanling Gan, Tongsheng Chu, Dianchang Liu
    Abstract:

    The shortage of Benzathine Penicillin G (BPG) worldwide presents a major challenge in the treatment of syphilis. Its availability for syphilis treatment has not been adequately evaluated in China. Two surveys were conducted among hospitals providing sexually transmitted infection clinical services in Shandong Province in 2012 and 2018. Data on the basic information and BPG availability of the surveyed hospitals and related factors were collected and analyzed using SPSS 17.0. A total of 433 and 515 hospitals were surveyed in 2012 and 2018, respectively. A significant difference in BPG availability was observed among different levels and types of hospitals both in 2012 (X2 = 9.747, p = 0.008; X2 = 37.167, p = 0.000) and 2018 (X2 = 11.775, p = 0.003; X2 = 28.331, p = 0.000). The BPG availability among surveyed hospitals increased from 45.0% in 2012 to 56.4% in 2018 (X2 = 11.131, p = 0.001). The BPG availability was higher in 2018 than in 2012 among county-level hospitals (52.0% vs. 40.8%, X2 = 7.783, p = 0.005), general western medicine hospitals (62.1% vs. 50.0%, X2 = 6.742, p = 0.009), maternal and child health hospitals (57.1% vs. 26.9%, X2 = 13.906, p = 0.000), and public hospitals (56.8% vs. 45.0%, X2 = 11.361, p = 0.001). However, the county-level availability of BPG (at least one hospital has BPG in a county-level unit) has not improved between 2012 and 2018 (65.93% vs. 70.34%; X2 = 0.563, p = 0.453). The absences of clinical needs, restriction of clinical antibacterial drugs, and lack of qualifications for providing syphilis treatment were the major reasons for the low BPG availability of hospitals. BPG availability for syphilis treatment in Shandong Province remains low and presents disparities among different levels and types of hospitals, although it has been improved in recent years. The low availability of BPG for syphilis treatment in China is related to its clinical use by doctors rather than the market supply. Health care reforms should further improve the availability and accessibility of health services.

  • Additional file 1: of Availability of Benzathine Penicillin G for syphilis treatment in Shandong Province, Eastern China
    2019
    Co-Authors: Xinlong Chen, Yanling Gan, Tongsheng Chu, Dianchang Liu
    Abstract:

    Questionnaire on availability of Benzathine Penicillin G in medical institutions. (DOCX 13 kb

  • Availability of Benzathine Penicillin G for syphilis treatment in Shandong Province, Eastern China
    BMC, 2019
    Co-Authors: Xinlong Chen, Yanling Gan, Tongsheng Chu, Dianchang Liu
    Abstract:

    Abstract Background The shortage of Benzathine Penicillin G (BPG) worldwide presents a major challenge in the treatment of syphilis. Its availability for syphilis treatment has not been adequately evaluated in China. Methods Two surveys were conducted among hospitals providing sexually transmitted infection clinical services in Shandong Province in 2012 and 2018. Data on the basic information and BPG availability of the surveyed hospitals and related factors were collected and analyzed using SPSS 17.0. Results A total of 433 and 515 hospitals were surveyed in 2012 and 2018, respectively. A significant difference in BPG availability was observed among different levels and types of hospitals both in 2012 (X2 = 9.747, p = 0.008; X2 = 37.167, p = 0.000) and 2018 (X2 = 11.775, p = 0.003; X2 = 28.331, p = 0.000). The BPG availability among surveyed hospitals increased from 45.0% in 2012 to 56.4% in 2018 (X2 = 11.131, p = 0.001). The BPG availability was higher in 2018 than in 2012 among county-level hospitals (52.0% vs. 40.8%, X2 = 7.783, p = 0.005), general western medicine hospitals (62.1% vs. 50.0%, X2 = 6.742, p = 0.009), maternal and child health hospitals (57.1% vs. 26.9%, X2 = 13.906, p = 0.000), and public hospitals (56.8% vs. 45.0%, X2 = 11.361, p = 0.001). However, the county-level availability of BPG (at least one hospital has BPG in a county-level unit) has not improved between 2012 and 2018 (65.93% vs. 70.34%; X2 = 0.563, p = 0.453). The absences of clinical needs, restriction of clinical antibacterial drugs, and lack of qualifications for providing syphilis treatment were the major reasons for the low BPG availability of hospitals. Conclusions BPG availability for syphilis treatment in Shandong Province remains low and presents disparities among different levels and types of hospitals, although it has been improved in recent years. The low availability of BPG for syphilis treatment in China is related to its clinical use by doctors rather than the market supply. Health care reforms should further improve the availability and accessibility of health services

  • availability of Benzathine Penicillin g for syphilis treatment in shandong province eastern china
    Social Science Research Network, 2018
    Co-Authors: Dianchang Liu, Tongsheng Chu, Xinlong Chen
    Abstract:

    Background: Penicillin is still an essential antibiotic for the treatment and prevention of syphilis. The shortage of Benzathine Penicillin G (BPG) worldwide presents a major challenge in the Penicillin treatment of syphilis. Its availability for syphilis treatment has not been adequately evaluated in China. Methods: Two surveys were conducted among hospitals providing sexually transmitted infection clinical services in Shandong Province in 2012 and 2018. Data on the basic information and BPG availability of the surveyed hospitals and related factors were collected and analyzed using SPSS 17·0. Findings: A total of 433 and 515 hospitals were surveyed in 2012 and 2018, respectively. A significant difference in BPG availability was observed among different levels and types of hospitals both in 2012 (X2=9·747, p=0·008; X2= 37·167, p=0·000) and 2018 (X2=11·775, p=0·003; X2= 28·331, p=0·000). The BPG availability among surveyed hospitals increased from 45·0% in 2012 to 56·4% in 2018 (X2=11·131, p=0·001). The BPG availability was higher in 2018 than in 2012 among county-level hospitals (52·0% vs. 40·8%, X2=7·783, p=0·005), general western medicine hospitals (62·1% vs. 50·0%, X2=6·742, p=0·009), maternal and child health hospitals (57·1% vs. 26·9%, X2=13·906, p=0·000), and public hospitals (56·8% vs. 45·0%, X2=11·361, p=0·001). However, the county-level availability of BPG (at least one hospital has BPG in a county-level unit) has not improved between 2012 and 2018 (65·93% vs. 70·34%; X2=0·563, p=0·453). The absences of clinical needs, restriction of clinical antibacterial drugs, and lack of qualifications for providing syphilis treatment were the major reasons for the low BPG availability of hospitals. Interpretation: The BPG availability for syphilis treatment in Shandong Province has been improved in recent years, although it remains low and presents disparities among different levels and types of hospitals. Its low availability for syphilis treatment in China is related to its clinical use by doctors rather than its market supply. Health care reforms should further improve availability and accessibility of health services. Funding: Shandong Provincial Key R&D Plan. Declaration of Interest: We declare no competing interests.

Chienching Hung - One of the best experts on this subject based on the ideXlab platform.

  • comparison of serological responses to single dose azithromycin 2 g versus Benzathine Penicillin g in the treatment of early syphilis in hiv infected patients in an area of low prevalence of macrolide resistant treponema pallidum infection
    Journal of Antimicrobial Chemotherapy, 2016
    Co-Authors: Chia-jui Yang, Szu-min Hsieh, Wang-huei Sheng, Kuan-yeh Lee, Hungjen Tang, Suiyuan Chang, Yuanti Lee, Shangping Yang, Chienching Hung
    Abstract:

    Objectives Effectiveness of single-dose azithromycin (2 g) in the treatment of early syphilis among HIV-infected patients has rarely been evaluated in the era of combination ART. Methods Consecutive HIV-infected patients with early syphilis, who received 2 g single-dose azithromycin or 2.4 MU Benzathine Penicillin G, between 2007 and 2014, were prospectively observed. Genotypic resistance to macrolides was determined in Treponema pallidum isolates identified from clinical specimens using PCR assays. Rapid plasma reagin (RPR) titres were determined at baseline and every 3 months after treatment. Primary outcome was a decline of RPR titre by ≥4-fold at 12 months after treatment. Results During the study period, 162 HIV-infected patients with early syphilis received Benzathine Penicillin G and 237 patients received azithromycin. At 12 months follow-up, the serological response rate for Penicillin and azithromycin groups was 61.1% and 56.5% (P = 0.41), respectively; respective response rate was 61.1% and 65.9% (P = 0.49) if we only included patients infected with T. pallidum not harbouring macrolide resistance in the azithromycin group. In multivariate analysis, RPR titres ≥1:32 (OR 2.56; 95% CI 1.55-4.21) and prior syphilis (OR 0.54; 95% CI 0.35-0.81) were predictors of serological response. Most common adverse effects of azithromycin included diarrhoea (52.7%), nausea (22.4%), abdominal pain (18.6%), bloating (17.7%) and lassitude/somnolence (27.4%). Conclusions In the setting of a low prevalence of macrolide-resistant T. pallidum, 2 g single-dose azithromycin achieved a similar serological response to Benzathine Penicillin G in HIV-infected patients with early syphilis. Major adverse effects of azithromycin were gastrointestinal symptoms and lassitude/somnolence.

Jen Chih Tsai - One of the best experts on this subject based on the ideXlab platform.